Indium-111-DTPA-octreotide scintigraphy modulation by treatment with unlabelled somatostatin analogue in small-cell lung cancer

E. Soresi, E. Bombardieri, A. Chiti, R. Boffi, G. Invernizzi, F. Crippa, L. Maffioli

Research output: Contribution to journalArticle

Abstract

Aims and background: Small-cell lung cancer (SCLC) tissue expresses somatostatin receptors and can be visualized by means of the indium-111-labelled somatostatin analogue DTPA-D-Phe-octreotide. The aim of the study was to investigate whether treatment with a cold somatostatin analogue can affect the imaging of somatostatin receptor scintigraphy. Methods: Three patients with SCLC were treated with 200 μg of cold octreotide three times a day subcutaneously for 7 days. Whole body and planar scintigraphy was performed before and after the treatment. Results: 111In-DTPA-octreotide uptake was increased in cancer lesions, whereas fixation in normal tissues (liver, spleen, kidneys) decreased. Conclusions: This is the first demonstration of an enhancement of SCLC imaging following unlabelled somatostatin analogue administration. Similar results have been described by other authors in a limited number of carcinoid tumors.

Original languageEnglish
Pages (from-to)125-127
Number of pages3
JournalTumori
Volume81
Issue number2
Publication statusPublished - 1995

Keywords

  • -In-DTPA-D-Phe-octreotide scintigraphy
  • octreotide treatment
  • small-cell lung cancer
  • somatostatin analogue

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Indium-111-DTPA-octreotide scintigraphy modulation by treatment with unlabelled somatostatin analogue in small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this